IN2014DN02014A - - Google Patents

Download PDF

Info

Publication number
IN2014DN02014A
IN2014DN02014A IN2014DEN2014A IN2014DN02014A IN 2014DN02014 A IN2014DN02014 A IN 2014DN02014A IN 2014DEN2014 A IN2014DEN2014 A IN 2014DEN2014A IN 2014DN02014 A IN2014DN02014 A IN 2014DN02014A
Authority
IN
India
Prior art keywords
compound
pregnan
ethynyl
diol
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Backstrom Torbjorn
Ragagnin Gianna
Original Assignee
Umecrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab filed Critical Umecrine Ab
Publication of IN2014DN02014A publication Critical patent/IN2014DN02014A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2014DEN2014 2006-11-21 2007-11-20 IN2014DN02014A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
PCT/SE2007/050876 WO2008063128A1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
IN2014DN02014A true IN2014DN02014A (cg-RX-API-DMAC7.html) 2015-07-10

Family

ID=39429970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2014DEN2014 IN2014DN02014A (cg-RX-API-DMAC7.html) 2006-11-21 2007-11-20

Country Status (16)

Country Link
US (9) US8580983B2 (cg-RX-API-DMAC7.html)
EP (4) EP2711372A1 (cg-RX-API-DMAC7.html)
JP (5) JP5386362B2 (cg-RX-API-DMAC7.html)
AU (1) AU2007322423C1 (cg-RX-API-DMAC7.html)
BR (2) BR122013033954B8 (cg-RX-API-DMAC7.html)
CA (2) CA2833976C (cg-RX-API-DMAC7.html)
DK (3) DK2097437T3 (cg-RX-API-DMAC7.html)
ES (3) ES2543841T3 (cg-RX-API-DMAC7.html)
HU (3) HUE033037T2 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN02014A (cg-RX-API-DMAC7.html)
MX (1) MX2009005335A (cg-RX-API-DMAC7.html)
PL (3) PL2792681T3 (cg-RX-API-DMAC7.html)
PT (1) PT2097437E (cg-RX-API-DMAC7.html)
RU (1) RU2458065C2 (cg-RX-API-DMAC7.html)
SI (1) SI2097437T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008063128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033037T2 (hu) 2006-11-21 2017-11-28 Umecrine Cognition Ab Pregnán és androsztán szteroidok alkalmazása központi idegrendszerbeli rendellenességek kezelésére szolgáló gyógyszerészeti készítmények elõállítására
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CA2786330C (en) 2010-01-14 2013-11-19 Umecrine Mood Ab A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
US20130203718A1 (en) * 2010-05-07 2013-08-08 Marie-Edith Rafestin-Oblin Progesterone receptor antagonists and uses thereof
SMT202300232T1 (it) 2011-09-08 2023-09-06 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e relativi usi
HRP20170503T1 (hr) * 2012-11-28 2017-06-16 Institut National De La Santé Et De La Recherche Médicale (Inserm) 3-(4'-supstituirani)-benzil-eter derivati pregnenolona
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
SI3099306T1 (sl) 2014-01-29 2019-03-29 Umecrine Cognition Ab Steroidna spojina za uporabo v zdravljenju hepatične encefalopatije
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SI3224269T1 (sl) * 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
TWI748936B (zh) * 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
BR122021005552B1 (pt) 2015-07-06 2024-01-02 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
AU2016289971C1 (en) 2015-07-06 2022-12-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
RU2019115112A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
KR102478510B1 (ko) 2017-02-10 2022-12-16 아사리나 파마 아베 의학적 치료에서 사용하기 위한 3-베타-히드록시-5-알파-프레그난-20-온
EP3579842A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
IL274893B2 (en) 2017-11-27 2024-08-01 Umecrine Cognition Ab Pharmaceutical formulation of 3 alpha-ethynyl-3 beta-hydroxyandrostan-17-one oxime
CN111918657A (zh) 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
CN115651054B (zh) 2019-01-08 2024-06-21 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
CN118251403A (zh) 2021-11-10 2024-06-25 梅克芳股份公司 用于调节GABA-A受体的α-3亚型的3.α.取代的3.β.-羟基17-肟化的雄甾烷化合物
EP4430056A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
EP4429669A1 (en) 2021-11-10 2024-09-18 Umecrine AB Steroid as a modulator of gabaa receptor
EP4389129A1 (en) * 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) * 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT808325E (pt) * 1994-11-23 2001-06-29 Cocensys Inc Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba
KR19990022323A (ko) * 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
AU756001B2 (en) 1998-03-11 2003-01-02 Umecrine Mood Ab Epiallopregnanolone in the treatment of CNS disorders
WO1999052532A1 (en) 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
CA2585359C (en) 2004-11-18 2013-01-08 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders
HUE033037T2 (hu) 2006-11-21 2017-11-28 Umecrine Cognition Ab Pregnán és androsztán szteroidok alkalmazása központi idegrendszerbeli rendellenességek kezelésére szolgáló gyógyszerészeti készítmények elõállítására
US20130203718A1 (en) 2010-05-07 2013-08-08 Marie-Edith Rafestin-Oblin Progesterone receptor antagonists and uses thereof

Also Published As

Publication number Publication date
HUE033037T2 (hu) 2017-11-28
CA2833976C (en) 2016-03-15
ES2607852T3 (es) 2017-04-04
PL2097437T3 (pl) 2015-12-31
US8853190B2 (en) 2014-10-07
PL2792681T3 (pl) 2017-06-30
CA2664126A1 (en) 2008-05-29
BRPI0718945B8 (pt) 2021-05-25
EP2097437A4 (en) 2012-12-26
HUE036410T2 (hu) 2018-07-30
BRPI0718945B1 (pt) 2020-10-13
ES2662500T3 (es) 2018-04-06
JP2013177411A (ja) 2013-09-09
JP2013173782A (ja) 2013-09-05
MX2009005335A (es) 2009-06-08
EP2792681B1 (en) 2016-10-19
BRPI0718945A2 (pt) 2013-12-24
US20140011793A1 (en) 2014-01-09
DK2097437T3 (en) 2015-06-29
US20140011779A1 (en) 2014-01-09
EP2097437B1 (en) 2015-05-27
US9200028B2 (en) 2015-12-01
EP2711372A1 (en) 2014-03-26
DK2792681T3 (en) 2017-01-23
BR122013033954B8 (pt) 2021-05-25
EP2097437A1 (en) 2009-09-09
JP5657052B2 (ja) 2015-01-21
RU2458065C2 (ru) 2012-08-10
BRPI0718945A8 (pt) 2017-09-19
AU2007322423A1 (en) 2008-05-29
RU2009107537A (ru) 2010-12-27
JP2010510210A (ja) 2010-04-02
US20130102579A1 (en) 2013-04-25
PL2711371T3 (pl) 2018-06-29
PT2097437E (pt) 2015-09-15
BR122013033954B1 (pt) 2021-01-12
US20080119416A1 (en) 2008-05-22
HUE026961T2 (en) 2016-07-28
JP2015147774A (ja) 2015-08-20
JP5918170B2 (ja) 2016-05-18
AU2007322423B2 (en) 2013-01-10
US20160272670A1 (en) 2016-09-22
EP2711371B1 (en) 2018-01-10
US20130281421A1 (en) 2013-10-24
CA2833976A1 (en) 2008-05-29
JP2013173781A (ja) 2013-09-05
US8580983B2 (en) 2013-11-12
US20140011792A1 (en) 2014-01-09
EP2711371A1 (en) 2014-03-26
AU2007322423C1 (en) 2013-08-15
ES2543841T3 (es) 2015-08-24
US20150315231A1 (en) 2015-11-05
CA2664126C (en) 2014-04-29
SI2097437T1 (sl) 2015-10-30
US20130102578A1 (en) 2013-04-25
EP2792681A1 (en) 2014-10-22
WO2008063128A1 (en) 2008-05-29
DK2711371T3 (en) 2018-04-16
JP5386362B2 (ja) 2014-01-15

Similar Documents

Publication Publication Date Title
IN2014DN02014A (cg-RX-API-DMAC7.html)
AP2402A (en) Amine derivatives.
AP2369A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
AP2193A (en) Control system for a pump.
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
SG143245A1 (en) Channel calibration for a time division duplexed communication system
LU92761I2 (en) N-(5-hydroxy-2,4-diert-butyl-phenyl)-4oxo-1h-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof
EA200801959A1 (ru) Высокоразветвленный полипропилен
IN2012DN02610A (cg-RX-API-DMAC7.html)
TNSN08191A1 (en) Kinase inhibitors
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
AP2339A (en) Herbicidal agents.
WO2009055289A3 (en) Therapeutic substituted lactams
GB2436104B (en) Vacuum valve for an I.S. machine
WO2007148102A3 (en) Crystalline duloxetine hydrochloride
EP1835059A4 (en) COMBINED CAM SYSTEM
WO2007134168A3 (en) Process for preparing duloxetine
WO2008014084A3 (en) Pipeline
MX2009006745A (es) Macrociclos de amino-tiazol, su uso como compuestos anti-bacterianos y procesos para su produccion.
AP2337A (en) Motilide compounds.
TW200621756A (en) Method for manufacturing enantiomeric imidazole compounds
TW200618799A (en) Method for manufacturing imidazole compounds and salts and pseudopolymorphs thereof
GB2431925B (en) Pushout mechanism for I.S. machine
FR2910232B1 (fr) Machine pour la fenaison, notamment andaineuse.
EP1889636A4 (en) ANTI-REFLEXE ENDOTRACHEAL TUBE BY V.A. PERVAK